A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, multicenter study designed to evaluate the preliminary
antineoplastic activity, safety and tolerability of HA121-28 tablets administered orally in
patients with medullary thyroid cancer (MTC).